Search Main Menu Main Content
  • Change contrast :
Retour à l'accueil du site de la HAS
logo HAS
icone
  • HAS profile
    • Mission
    • Organisational Structure
    • Ethics, transparency and management of conflicts of interest
  • International relations and projects
  • Publications
  1. Industriels
  2. Médicament
  3. FARLUTAL (acétate de médroxyprogestérone)
  • icone plus
  • My account

    • Email alert Subscription
    • Newsletter Subscription
    • My search
    Refresh
    Please fill in your email address to retrieve your email alerts subscriptions.
    New subscription
    Please fill in your email address to retrieve your newsletter subscriptions.

    You do not have a saved search

    Mon Compte
  • No element in selection

    Favoris
  • Établissements de santé
  • Contact Abonnez-vous aux actualités
Listen Listen
Add to my selection
  • History
  • Technical informations
Share
Share on
Facebook share - facebook.com - new window
Tweeter share - Partager sur Twitter - twitter.com - new window
LinkedIn share - linkedin.com - new window
Print

FARLUTAL (acétate de médroxyprogestérone)

Medicine - Posted on Feb 16 2011 - Updated on Jun 12 2019
Active substance (DCI)
  • acétate de médroxyprogestérone
history (2)
  • 2/16/11

    FARLUTAL (acétate de médroxyprogestérone)

    FARLUTAL (acétate de médroxyprogestérone)
    icône flèche
  • 11/16/05

    FARLUTAL 500 mg, comprimé B/30 (CIP: 326 573-3) FARLUTAL 500 mg/2,5 ml, suspension injectable (I.M.) à libération prolongée B/1 flacon de 2,5 ml (CIP: 314 499-8)

    FARLUTAL 500 mg, comprimé B/30 (CIP: 326 573-3) FARLUTAL 500 mg/2,5 ml, suspension injectable (I.M.) à libération prolongée B/1 flacon de 2,5 ml (CIP: 314 499-8)
    icône flèche
Technical information
ATC code
  • L02AB02
Manufacturer
Laboratoire PFIZER
Presentation

FARLUTAL 500 mg, comprimé Boîte de 30 - Code CIP : 3265733

FARLUTAL 500 mg/2,5 ml, suspension injectable (I.M.) à libération prolongée Boîte de 1 flacon - Code CIP : 3144998

All our publications
    Breast cancers Drug therapy Eating and sleep disorders Genital cancers

Follow us :

  • Twitter (nouvelle fenêtre)
  • Facebook (nouvelle fenêtre)
  • Youtube (nouvelle fenêtre)
  • LinkedIn (nouvelle fenêtre)
Haute Autorité de Santé
Advancing quality in the fields of health and social care services
  • Eunetha.eu
  • Pasq.eu
  • All our publications by topic and type
  • Opinions on medicines
  • Opinions on medical devices
  • INAHTA briefs
  • Français
  • English
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
3LmEAj1WbbKnHTWP